Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

In an open-label, randomized, noninferiority trial, dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 385; no. 27; pp. 2531 - 2543
Main Authors: Turkova, Anna, White, Ellen, Mujuru, Hilda A, Kekitiinwa, Adeodata R, Kityo, Cissy M, Violari, Avy, Lugemwa, Abbas, Cressey, Tim R, Musoke, Philippa, Variava, Ebrahim, Cotton, Mark F, Archary, Moherndran, Puthanakit, Thanyawee, Behuhuma, Osee, Kobbe, Robin, Welch, Steven B, Bwakura-Dangarembizi, Mutsa, Amuge, Pauline, Kaudha, Elizabeth, Barlow-Mosha, Linda, Makumbi, Shafic, Ramsagar, Nastassja, Ngampiyaskul, Chaiwat, Musoro, Godfrey, Atwine, Lorna, Liberty, Afaaf, Musiime, Victor, Bbuye, Dickson, Ahimbisibwe, Grace M, Chalermpantmetagul, Suwalai, Ali, Shabinah, Sarfati, Tatiana, Wynne, Ben, Shakeshaft, Clare, Colbers, Angela, Klein, Nigel, Bernays, Sarah, Saïdi, Yacine, Coelho, Alexandra, Grossele, Tiziana, Compagnucci, Alexandra, Giaquinto, Carlo, Rojo, Pablo, Ford, Deborah, Gibb, Diana M
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 30.12.2021
Subjects:
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first